ONCO — Onconetix, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1782107 ·
Last close
$0.83
Market Cap
$3.05M
52W High
$6.72
52W Low
$0.67
ADV30
628,950
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 21,457 | -1,655 | -2,091,801 | -4,214,875 | 14,832,086 | 3,716,072 | 3,083,885 |
| Dec 2025 | 303,596 | 247,684 | -1,281,367 | 5,669,687 | 24,926,638 | 5,220,654 | 9,160,287 |
| Sep 2025 | 303,651 | 268,894 | -2,069,242 | -8,783,702 | 19,678,868 | 836,556 | 16,303,023 |
| Jun 2025 | 106,494 | 70,503 | -1,341,418 | -2,372,442 | 19,119,036 | 283,515 | 13,209,275 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,800,191
Investing CF
$0
Financing CF
$12,214,220
CapEx
$-6,187
Dividends Paid
—
Buybacks
$-395,933
EPS Diluted TTM
$-2890.10
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-135,429,433
Inventory
$137,642
Receivables
$100,063
ST Investments
—
EBIT TTM
$-9,171,150
Pretax Income TTM
$-9,700,807
Interest Exp TTM
$529,657
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$735,198
EBITDA
$-6,768,008
Free Cash Flow
$-6,337,745
Enterprise Value
$-2,478,374
Total Cash
$3,716,072
Total Debt
$289,922
Shares Out
3,691,492
Trailing EPS
$1377.40
Book Value
$42.63
ROE
-123.3%
ROA
-25.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 815,371 | -6,344,856 | -14,032,342 | 24,926,638 | 9,160,287 | — | -9,678,390 |
| Dec 2024 | 2,524,116 | -10,331,243 | -58,691,023 | 28,181,563 | 18,571,008 | — | -10,495,816 |
| Dec 2023 | 58,465 | -17,847,249 | -37,409,694 | 87,518,032 | 86,113,556 | — | -13,581,018 |
| Dec 2022 | 0 | -13,481,240 | -13,419,830 | 26,310,447 | 3,922,445 | — | -8,675,534 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACUT | Accustem Sciences Inc. | $3.05M | $0.19 | — |
| PRFX | PRF Technologies Ltd. | $3.04M | $1.00 | — |
| GNPX | Genprex, Inc. | $3.02M | $5.99 | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $3.11M | $1.17 | — |
| ADTX | Aditxt, Inc. | $2.99M | $0.00 | — |
News headlines (Yahoo Finance, 1h cache)
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
2026-07-07 13:00 · Yahoo
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
2026-06-24 12:30 · Yahoo
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
2026-05-19 12:00 · Yahoo
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
2026-05-13 13:25 · Yahoo
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
2026-04-17 23:00 · Yahoo
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
2026-04-09 12:30 · Yahoo
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
2026-04-07 22:00 · Yahoo
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
2026-04-02 12:30 · Yahoo
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
2026-03-31 12:30 · Yahoo
BC-Most Active Stocks
2026-03-27 14:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.